12 citations
,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
1 citations
,
October 2025 in “Gels” Nanogels with hydrophobic modifications improve oral drug delivery for intestinal disease treatment.
January 2018 in “Food Additives and Contaminants Part A-chemistry Analysis Control Exposure & Risk Assessment” Researchers developed a precise method to detect illegal hair-growth drugs in dietary supplements.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
October 2012 in “Sax's Dangerous Properties of Industrial Materials” 1 citations
,
December 2011 in “Arzneimittelforschung” The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference”
33 citations
,
December 2023 in “Cell Death Discovery” Cepharanthine may help treat gastric cancer by causing cancer cell death and affecting energy use.
1 citations
,
March 2023 in “Science Translational Medicine” Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
September 2019 in “Journal of Investigative Dermatology” EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.
4 citations
,
May 2023 in “Research Square (Research Square)” Cepharanthine can potentially treat gastric cancer by stopping tumor growth.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
January 2025 in “Regenerative Biomaterials” The cerium-polypeptide hydrogel effectively heals drug-resistant bacterial wounds by fighting bacteria, reducing inflammation, and promoting tissue repair.
13 citations
,
January 2005 in “Chemical and Pharmaceutical Bulletin” Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
December 2023 in “European Journal of Pharmacology” C3G and Vitisin A may help prevent hair loss by blocking male hormones and stopping hair cell death.
IP-PA1 helps grow hair in mice and affects human cell growth-related genes differently than traditional hair growth treatments.
57 citations
,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
June 2025 in “Dermatologic Surgery” GFC improves hair quickly, while PRP offers longer-lasting benefits; using both sequentially is recommended.
February 2026 in “Frontiers in Medicine” Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.
51 citations
,
June 2021 in “Signal Transduction and Targeted Therapy” The document concludes that while there are promising methods to control CRISPR/Cas9 gene editing, more research is needed to overcome challenges related to safety and effectiveness for clinical use.
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
11 citations
,
August 2021 in “Stem Cell Research & Therapy” Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
6 citations
,
March 2024 in “Saudi Pharmaceutical Journal” The new delivery system could improve pain and inflammation relief in gout.